CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health CanSino Biologics Inc Jun 20, 2025 18:06 HKT/SGT Read More
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China Eisai May 28, 2025 16:45 HKT/SGT Read More
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025 Eisai May 21, 2025 14:00 HKT/SGT Read More
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro Eisai May 16, 2025 16:21 HKT/SGT Read More
Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China Everest Medicines Limited May 07, 2025 18:06 HKT/SGT Read More
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star Eisai Apr 30, 2025 13:17 HKT/SGT Read More
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union Eisai Apr 18, 2025 15:52 HKT/SGT Read More
エーザイとバイオジェン、「レケンビ」（レカネマブ）が欧州連合（EU）において早期アルツハイマー病の進行を抑制する初めての治療剤として承認を取得 Eisai Apr 16, 2025 11:30 JST Read More
SinoMab BioScience Limited Breakthrough Phase 1b POC Results for SM17 in Atopic Dermatitis SinoMab BioScience Limited Apr 09, 2025 14:49 HKT/SGT Read More
エーザイ、アルツハイマー・パーキンソン病学会において、レカネマブの長期実臨床データやバイオマーカーをはじめとするアルツハイマー病の最新成果を発表 Eisai Mar 27, 2025 08:40 JST Read More
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards Eisai Mar 25, 2025 16:28 HKT/SGT Read More
エーザイ、日本発 世界初の早期アルツハイマー病治療剤「レケンビ」が第 12 回技術経営・イノベーション大賞において「内閣総理大臣賞」を受賞 Eisai Mar 25, 2025 15:30 JST Read More
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace Eisai Mar 25, 2025 11:21 HKT/SGT Read More
Dr. Li Chen Honored as A Leading Figure in Shanghai's Industry and Commerce Hua Medicine Mar 18, 2025 22:36 HKT/SGT Read More
